Patent · US Active

C-RAF mutants that confer resistance to RAF inhibitors

US9629839B2 · kind B2 · utility

1Cited by

1References

5Claims

0Family size

Assignee

DANA-FARBER CANCER INSTITUTE, INC. · US

Inventors

Caroline Emery · Brookline, US
Rajee Antony · Norwood, US
Levi A. Garraway · Newton, US

Key dates

Filing date	Mar 7, 2013
Grant date	Apr 25, 2017
Priority date	—
Expiry date	Mar 31, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y207/11001
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Nucleic acids and proteins having a mutant C-RAF sequence, and methods of identifying patients having cancer who are likely to benefit from a combination therapy and methods of treatment are provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.